The main aim of our study was to test the hypothesis that IGF1R, and the downstream IGF signal transduction pathway and phenotypic response [37], is important and hence a viable therapeutic target in gastric cancer cells that are not addicted to HER2, FGFR2 or MET and are ineligible for HER2-, FGFR- or MET-targeted therapies. This evidence concerns the gene ERBB2 and gastric cancer.